Rinsho Shinkeigaku (Clinical Neurology)

Symposium 3

Cell therapy for stroke

Osamu Honmou, M.D., Ph.D.1)

1)Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine Sapporo Medical University

Intravenous transplantation of mesenchymal stem cells (MSCs) derived from bone marrow has been reported to ameliorate functional deficits in several CNS diseases. The objectives of this presentation were to show feasibility and safety of cell therapy using auto serum-expanded autologous MSCs in stroke. Twelve (male and female) patients with stroke were enrolled. Cryopreserved MSCs were thawed and injected intravenously into patients over 30 min. Serial evaluations showed no severe adverse cell-related effects. In patients with cerebral infarcts, the intravenous administration of autologous MSCs appears to be feasible and safe, and merits further study as a therapy that may improve functional recovery.
Full Text of this Article in Japanese PDF (611K)

(CLINICA NEUROL, 53: 1175|1176, 2013)
key words: stroke

(Received: 31-May-13)